5.51
5.51 (0%)
As of Feb 14, 2025
Personalis, Inc. [PSNL]
Source:
Company Overview
Personalis develops, markets, and sells advanced cancer genomic tests and services. Our services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials. Our tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection.
| Country | United States |
| Headquarters | fremont, california |
| Phone Number | 650-752-1300 |
| Industry | services |
| CEO | Christopher Hall |
| Website | https://www.personalis.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $84.6 |
| Operating Profit | $-68.3 |
| Net Income | $-81.3 |
| Net Cash | $34.4 |
Profit Ratios
| Gross Margin | $26.8 |
| Operating Margin | -80.7 |
| Profit as % of Revenues | -33% |
| Profit as % of Assets | -60.2% |
| Profit as % of Stockholder Equity | -40.1% |
Management Effectiveness
| Return on Equity | -40.1% |
| Return on Assets | -30.1% |
| Turnover Ratio | 62.6% |
| EBITA | $-68.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $270.3 |
| Total Liabilities | $67.3 |
| Operating Cash Flow | $-45.2 |
| Investing Cash Flow | $-35.1 |
| Financing Cash Flow | $114.7 |
